{"id":91273,"title":"Omega Diagnostics Gp (ODX.L) DHSC contract update","publisher":"Share Talk","author":"sharetalk","published":"2021-12-10T12:25:25+00:00","modified":"2021-12-10T12:25:25+00:00","canonical_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-dhsc-contract-update/","markdown_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-dhsc-contract-update.md","json_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-dhsc-contract-update.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical"],"tags":["Abingdon Health","Administration","Antigen Test","china","Colin King","Contract","COVID-19","David Grouse","diagnostic","diseases","Drug","Food","infectious","Manufacturing","Medical","Mologic Ltd","ODX","Omega Diagnostics","Omega Diagnostics Gp","Rapid Test","scientists","Screen4","UK Government","UK-RTC","University of Oxford"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Omega (AIM: ODX),** the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, provides an update in relation to the Company’s contract with the Department of Health and Social Care (“DHSC”) to provide manufacturing capacity for COVID-19 lateral flow antigen tests.\n\nAs previously disclosed, the DHSC was unable to move into Phase 2 of the contract, which would have seen Omega progress to manufacturing tests using Government-furnished equipment.\n\nOmega has received confirmation from the DHSC that they acknowledge that the contract expired on 1 October 2021 and a request that Omega submit a proposal for the repayment of the pre-production payment of £2.5m (net of VAT).\n\nThe Board of Omega, having taken initial legal advice, do not believe that the Company is required to repay the pre-production payment and will respond in writing as requested. The Board will continue to take further legal advice on this matter and hopes to reach a resolution swiftly.\n\n**Colin King, CEO, Omega Diagnostics, said**: “It is clearly disappointing to receive this request for repayment given the efforts we have gone to ensure manufacturing capacity for COVID-19 lateral flow test was available for the DHSC and that we did not progress to Phase 2 of the contract due to the lack of confirmation from the DHSC regarding which test they require us to manufacture.\n\n“Acting in good faith we used these pre-production payments, along with our own funds, to upgrade our manufacturing facilities to be able to integrate the Government-furnished equipment and bringing on the additional staff required to be able to supply the DHSC using our UK-based volume manufacturing services. We therefore are confident that, having sought legal advice, we will not be required to make this repayment.”\n\n**Contacts:**\n\n**Omega Diagnostics Group PLC**\n\n[www.omegadx.com](http://www.omegadx.com)\n\n**Colin King, Chief Executive Officer**\n\n**via Walbrook PR**\n\n**Chris Lea, Chief Financial Officer**"}